News

Trikafta Increases Microbiome Diversity in Lungs, Study Shows

The microbiome diversity in the lungs of cystic fibrosis (CF) patients increased after treatment with Trikafta, becoming similar to a person without CF, an analysis showed. In addition, small molecule metabolites produced by cells varied widely across patients while on the therapy, with the largest decrease seen in…

Lung Airway Chip Accurately Models Cystic Fibrosis

For the first time, many features of cystic fibrosis (CF) were modeled accurately in a human Lung Airway Chip lined with cells from CF patients, which included enhanced mucus secretion, inflammation, and microbial infections, a study has shown. This “organ-on-a-chip model” of the disease may support the rapid development…

P. Aeruginosa Metabolites May Enable Better Patient Management

Molecules produced by the environmental bacteria Pseudomonas aeruginosa, called alkyl-quinolones derivatives — which regulate bacterial gene activity and act in cell-to-cell communication — may be useful markers for better management of patients with cystic fibrosis (CF), a study suggests. These derivatives also may enable a more clear definition…

CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6

A branch of the European Medicines Agency (EMA) has recommended expanding Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP),…

Elexacaftor Also Works as CFTR Potentiator, Study Says

Elexacaftor (VX-445), a next-generation CFTR corrector that is part of the triple-combination therapy Trikafta, is also a potentiator, a study reports. Results further showed that in combination with ivacaftor, sold as Kalydeco and also a potentiator, elexacaftor boosts ion flow across CFTR, the…